In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Engaging Consumers In The Microbiome

Executive Summary

uBiome combines crowdsourcing, citizen science, and the latest in robotics and sequencing to generate microbiome-related Big Data for organizations, as well as raise money, and interest, via its consumer kits.

Founded by University of California, San Francisco scientists and Stanford University and University of Cambridge technologists, uBiome Inc. combines crowdsourcing, citizen science, and the latest in robotics and sequencing to generate microbiome-related Big Data for organizations, as well as raises money, and interest, via its consumer kits. It’s about “equipping individuals to learn about the unique balance of bacteria in their bodies,” the company’s web site declares. Individuals receive a swab kit, take a sample (e.g. from the mouth or nose), fill in a questionnaire, and send it all off. They can then compare their microbiomes with those of, say, vegetarians, endurance athletes, or people taking antibiotics. It’s another angle on the “quantified self” movement driving funding for hundreds of health-related wearables, typically consumed by health and fitness enthusiasts. uBiome also has a social mission, it says, including to promote microbiome research in developing countries. The company raised $4.5 million in angel funding in August 2014, after bringing in $1.5 million in seed money from Andreessen Horowitz in June 2014.

Launched in 2012, OpenBiome, a non-profit stool bank, treats patients with infected guts even though neither its samples nor its procedures are FDA approved. The agency is using “enforcement discretion” to allow the process to continue – given the strong evidence of effectiveness and lack of alternatives – though this may change in the future. OpenBiome carefully selects its (paid) donors who must undergo in-depth clinical checks and have a BMI of less than 30. Samples are screened, filtered, and frozen. The company claims its treatment has an 89% success rate and is expanding the service. Its mission is to facilitate universal access to fecal microbiota transplantation.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel